Monoclonal antibodies (mAbs) are produced by clones of a unique parent cell
which has monovalent affinity and can bind to the same epitope. The chronological breakthrough
in mAbs clinical utilization was in 1975, when it becomes possible to produce
mAbs to known antigens and immortalize the cell lines. However, the clinical usefulness of
mAbs was hampered for many years, basically because of their immunogenicity due to the
murine origin. This situation lasted until 1988 when a technique to humanize mAbs was defined. Nuclear
Medicine researchers were very quick to gathered the opportunity provided by the development of mAbs. The
first papers reporting the preclinical use of radiolabelled mAbs date the early 80’s soon followed by the first
pivotal use in humans. However, mAbs did not gain a wide clinical use for several reasons connected to the
chemistry and biochemistry of radiolabelled mAbs the emergence of clinical 18F-FDG PET. However, the
“magic bullet” concept has resisted in the cultural background of Nuclear Medicine physicians for almost
twenty years, and has regained importance with the development of engineered mAbs. Herein we present a
selected review of preclinical and clinical studies of PET/CT with mAbs in gastrointestinal malignancies.
Keywords: ImmunoPET, Gastrointestinal tract neoplasms, Liver neoplasms, Pancreatic neoplasms.
Rights & PermissionsPrintExport